Clinical trial · Observational
Pathological Results of Aggressive Hepatocellular Carcinomas Treated Using SIRT
Pathological Results After Downstaging of Agressive Hepatocellular Carcinoma Using 90Y-SIRT With Personalized Dosimetry
NCT05045573CI-TRIAL-00054321PAHCHScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of our study is to analyze pathological analysis of surgically treated aggressive hepatocellular carcinomas after radio-embolization. The investigators aim to demonstrate that a higher dose results in better tumor response while respecting safety conditions, that is, no radiologically induced liver disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Pathological tumor response
- timeFrame
- 6 months
- description
- Patients are treated with SIRT, then if the tumor response was adequate, surgery was performed.Analysis after surgery. (6 months after SIRT)
Secondary outcomes (1)
- measure
- Rate of Healthy liver hypertrophia
- timeFrame
- day 1
- description
- Rate of Healthy liver hypertrophia
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: \- aggressive hepatocellular carcinomas with vascular invasion, large tumors or multifocal distribution Exclusion criteria: * Other treatment after SIRT (confounding effect) * contraindications for surgery
References
Publications (1)
- DERIVEDMeerun MA, Allimant C, Riviere B, Herrero A, Panaro F, Assenat E, Cassinotto C, Mariano-Goulart D, Guiu B. Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery. Hepatobiliary Surg Nutr. 2023 Jun 1;12(3):351-365. doi: 10.21037/hbsn-22-184. Epub 2022 Oct 31. PMID 37351147